Published in J Exp Pharmacol on August 27, 2010
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med (2009) 6.84
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med (2004) 6.42
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr (2004) 5.88
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem (2007) 4.74
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell (2007) 4.71
Update in vitamin D. J Clin Endocrinol Metab (2010) 4.48
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology (2007) 3.46
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab (2010) 2.70
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol (2010) 2.17
Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med (2009) 2.02
Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J (2008) 1.96
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95
Secondary causes of osteoporosis. Mayo Clin Proc (2002) 1.86
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv (2008) 1.61
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas (2010) 1.51
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res (2006) 1.44
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (2009) 1.41
Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med (2005) 1.40
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril (2009) 1.22
Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev (2006) 1.19
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
Bone loss in relation to menopause: a prospective study during 16 years. Bone (2001) 1.14
The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther (2010) 1.09
Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int (2008) 1.06
Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int (2007) 1.02
Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res (2009) 1.00
Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol (2005) 0.98
Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging (2007) 0.97
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone (2009) 0.97
Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets (2008) 0.94
The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep (2005) 0.92
Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int (2002) 0.92
Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling. Horm Metab Res (2010) 0.91
Biology of bone and how it orchestrates the form and function of the skeleton. Eur Spine J (2001) 0.91
Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol (2008) 0.91
How to decide who to treat. Best Pract Res Clin Rheumatol (2009) 0.90
Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag (2008) 0.87
Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. Menopause (2009) 0.87
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging (2010) 0.87
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs (2006) 0.86
Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int (2009) 0.85
Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig (2009) 0.85
Treatment of osteoporosis with denosumab. Maturitas (2010) 0.85
Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther (2008) 0.85
Raloxifene use in clinical practice: efficacy and safety. Menopause (2009) 0.84
Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int (1994) 0.84
New insights into the mechanisms involved in the pleiotropic actions of 1,25dihydroxyvitamin D3. Ann N Y Acad Sci (2006) 0.83
Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review. Sao Paulo Med J (2008) 0.81
Monitoring pharmacological therapy for osteoporosis. Rev Endocr Metab Disord (2010) 0.77
ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs (2008) 0.77
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2009) 0.77
Developing drugs to treat osteoporosis: lessons learned? Expert Opin Pharmacother (2010) 0.77
Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res (1997) 0.77
What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study. J Public Health (Oxf) (2010) 0.76
Etridronate therapy in the treatment and prevention of osteoporosis. J Clin Densitom (2000) 0.75